Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Holtzman
Washington University, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
C2N Diagnostics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the Conflicts of Interest Review Committee determined Dr. Holtzman’s personal financial relationship with C2N, related to the above mentioned research, creates a financial conflict of interest due to the following reasons:
• His personal financial relationship with C2N is directly related to the research because the research is evaluating a technology developed by Dr. Holtzman (tau antibodies), which has been licensed to C2N.
• Since he owns equity in the company and will earn royalties from the sale and distribution of the licensed technology, Dr. Holtzman could directly benefit, should the company’s equity value increase as a result of these studies.
• His role in the research project as a mentor could directly affect the research.
Note that while the CIRC determined Dr. Holtzman has a financial conflict of interest, the following elements were determined to help offset the risks posed by the conflict:
• The research is basic in nature and in its early stages.
• The Conflicts of Interest Review Committee understands the emphasis of his research is preclinical (animal studies) and does not focus on the humanized tau antibodies. Thus, the research is unlikely to directly affect the royalties related to the licensed IP.
• Additionally, a plan has been developed to mitigate his financial conflict of interest.
Molecular approaches for understanding and advancing tau immunotherapies
Project Narrative According the Center for Disease Control and the Alzheimer's Association, Alzheimer's disease (AD) is the 6th leading cause of death in the United States, currently affecting 5.3 million Americans with the costs totaling upwards of $215 billion annually, and unless a cure or treatment is developed these numbers are projected to triple by 2050. The use of monoclonal antibodies has proven a potent immunotherapeutic in various cancers and autoimmune disorders and is now being investigated in AD. Therefore, the goal of our research is to understand how monoclonal antibodies targeting one of the main pathological proteins contributing to AD and related dementias, tau, function to reduce tau-associated pathology and improve cognition as well as develop sustainable methods for delivering anti-tau monoclonal antibodies using a gene therapy approach.
Filed on November 03, 2016.
Tell us what you know about David Holtzman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Holtzman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly | $0 - $4,999 |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Therapeutics | $20,000 - $39,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | $10,000 - $19,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly and Company | $0 - $4,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.